Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: A consortium for improving survival of lymphoma (CISL) trial

Investigational New Drugs

Volumn 29, Issue 1, 2011, Pages 154-160

  Park, Byeong Bae ^a   Kim, Won Seog ^b   Eom, Hyeon Seok ^c   Kim, Jin Seok ^d   Lee, Young Yiul ^a   Oh, Suk Joong ^e   Lee, Dae Ho ^f   Suh, Cheolwon ^f  

^a Hanyang University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c National Cancer Center   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

Author keywords

Gemcitabine; Non Hodgkin's lymphoma; Salvage therapy

Indexed keywords

DEXAMETHASONE; GEMCITABINE; IFOSFAMIDE; OXALIPLATIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN CELL; INFECTION; KIDNEY FUNCTION; LARGE CELL LYMPHOMA; LIVER FUNCTION; MALE; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; RASH; SALVAGE THERAPY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; DEOXYCYTIDINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IFOSFAMIDE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SALVAGE THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79151473479     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9320-y     Document Type: Article

References (28)

1. T Philip C Guglielmi A Hagenbeek R Somers H Van der Lelie D Bron P Sonneveld C Gisselbrecht JY Cahn JL Harousseau, et al. 1995 Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med 333 1540 1545 1:STN:280:DyaK28%2FmslCgtQ%3D%3D 10.1056/NEJM199512073332305 7477169
2. W Mills R Chopra A McMillan R Pearce DC Linch AH Goldstone 1995 BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma J Clin Oncol 13 588 595 1:STN:280:DyaK2M7ptVGjtQ%3D%3D 7884420
3. P Schutt J Passon P Ebeling A Welt S Muller K Metz T Moritz S Seeber MR Nowrousian 2007 Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas Eur J Haematol 78 93 101 1:STN:280:DC%2BD2s7hvVensg%3D%3D 10.1111/j.1600-0609.2006.00796.x 17313557
4. C Wheeler M Strawderman L Ayash WH Churchill BE Bierer A Elias DG Gilliland K Antman EC Guinan JP Eder, et al. 1993 Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide J Clin Oncol 11 1085 1091 1:STN:280:DyaK3s3nsVegsQ%3D%3D 8099120
5. A Aviles N Neri J Huerta-Guzman R Fernandez 2004 Gemcitabine and cisplatin in refractory malignant lymphoma Oncology 66 197 200 1:CAS:528:DC%2BD2cXlt1Sltbw%3D 10.1159/000077995 15218310
6. M Crump T Baetz S Couban A Belch D Marcellus K Howson-Jan K Imrie R Myers G Adams K Ding N Paul L Shepherd J Iglesias R Meyer 2004 Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) Cancer 101 1835 1842 1:CAS:528:DC%2BD2cXptlKqt7o%3D 10.1002/cncr.20587 15386331
7. Ng M, Waters J, Cunningham D, Chau I, Horwich A, Hill M, Norman AR, Wotherspoon A, Catovsky D 2005 Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma Br J Cancer 92 1352 1357 10.1038/sj.bjc.6602514
8. M Hanel N Kroger MM Hoffknecht SO Peters B Metzner F Fiedler D Braumann JC Schubert HJ Illiger A Hanel WH Kruger W Zeller HJ Weh DK Hossfeld AR Zander 2000 ASHAP-an effective salvage therapy for recurrent and refractory malignant lymphomas Ann Hematol 79 304 311 1:CAS:528:DC%2BD3cXktFCmsrg%3D 10.1007/s002779900150 10901609
9. WS Velasquez F Cabanillas P Salvador P McLaughlin M Fridrik S Tucker S Jagannath FB Hagemeister JR Redman F Swan, et al. 1988 Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) Blood 71 117 122 1:STN:280:DyaL1c%2FnvVemsQ%3D%3D 3334893
10. WS Velasquez P McLaughlin S Tucker FB Hagemeister F Swan MA Rodriguez J Romaguera E Rubenstein F Cabanillas 1994 ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study J Clin Oncol 12 1169 1176 1:STN:280:DyaK2c3mtValsQ%3D%3D 8201379
11. FB Hagemeister 1999 The role of ifosfamide in the treatment of lymphomas Leuk lymphoma 34 433 441 1:CAS:528:DC%2BD3cXntV2gsrY%3D 10492066
12. CH Moskowitz JR Bertino JR Glassman EE Hedrick S Hunte N Coady-Lyons DB Agus A Goy J Jurcic A Noy J O'Brien CS Portlock DS Straus B Childs R Frank J Yahalom D Filippa D Louie SD Nimer AD Zelenetz 1999 Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma J Clin Oncol 17 3776 3785 1:CAS:528: DC%2BD3cXhsVCitA%3D%3D 10577849
13. G Corazzelli F Russo G Capobianco G Marcacci P Della Cioppa A Pinto 2006 Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study Ann Oncol Suppl 4 iv18 24 10.1093/annonc/mdj994
14. A Goldin 1982 Ifosfamide in experimental tumor systems Semin Oncol 9 14 23 1:CAS:528:DyaL3sXhtlKqu78%3D 6761864
15. BD Cheson B Pfistner ME Juweid RD Gascoyne L Specht SJ Horning B Coiffier RI Fisher A Hagenbeek E Zucca ST Rosen S Stroobants TA Lister RT Hoppe M Dreyling K Tobinai JM Vose JM Connors M Federico V Diehl 2007 Revised response criteria for malignant lymphoma J Clin Oncol 25 579 586 10.1200/JCO.2006.09.2403 17242396
16. R Simon 1989 Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 10 1:STN:280:DyaL1M7ps1SjsQ%3D%3D 10.1016/0197-2456(89) 90015-9 2702835
17. RE Millikan WK Plunkett TL Smith DL Williams CJ Logothetis 2001 Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin Cancer 92 194 199 1:CAS:528:DC%2BD3MXls1enurs%3D 10.1002/1097-0142(20010701)92:1<194::AID- CNCR1309>3.0.CO;2-3 11443627
18. ES Papageorgiou P Tsirigotis M Dimopoulos N Pavlidis G Fountzilas S Papageorgiou T Economopoulos 2005 Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group Eur J Haematol 75 124 129 1:CAS:528:DC%2BD2MXoslCqtLg%3D 10.1111/j.1600-0609.2005. 00482.x 16000128
19. I Aurer N Durakovic I Radman D Nemet S Zupancic-Salek J Kovacevic-Metelko V Bogdanic D Sertic M Mrsic M Mikulic B Labar 2002 Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective study Croat Med J 43 550 554 12402394
20. MA Rodriguez FC Cabanillas W Velasquez FB Hagemeister P McLaughlin F Swan JE Romaguera 1995 Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP J Clin Oncol 13 1734 1741 1:STN:280:DyaK2MzisFyqsQ%3D%3D 7602363
21. A Santoro M Magagnoli M Spina G Pinotti L Siracusano M Michieli A Nozza B Sarina E Morenghi L Castagna U Tirelli M Balzarotti 2007 Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma Haematologica 92 35 41 1:CAS:528: DC%2BD2sXitlOrt7k%3D 10.3324/haematol.10661 17229633
22. F Recchia S De Filippis M Rosselli P Pompili G Guerriero S Rea 1999 Ifosfamide, vinorelbine and gemcitabine in advanced non-small cell lung cancer. A phase I study Eur J Cancer 35 1457 1461 1:CAS:528:DyaK1MXmsVWisL4%3D 10.1016/S0959-8049(99)00147-1 10673977
23. B Sirohi D Cunningham A Norman K Last I Chau A Horwich J Oates G Chong A Wotherspoon 2007 Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL) Hematology (Amsterdam, Netherlands) 12 149 153 1:CAS:528:DC%2BD2sXmvVWmtLs%3D
24. Corazzelli G, Capobianco G, Arcamone M, Ballerini PF, Iannitto E, Russo F, Frigeri F, Becchimanzi C, Marcacci G, De Chiara A, Pinto A (2009) Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer chemother pharmacol
25. E Hoster M Dreyling W Klapper C Gisselbrecht A van Hoof HC Kluin-Nelemans M Pfreundschuh M Reiser B Metzner H Einsele N Peter W Jung B Wormann WD Ludwig U Duhrsen H Eimermacher H Wandt J Hasford W Hiddemann M Unterhalt 2008 A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma Blood 111 558 565 1:CAS:528:DC%2BD1cXns1Cgtw%3D%3D 10.1182/blood-2007-06-095331 17962512
26. T El Gnaoui J Dupuis K Belhadj JP Jais A Rahmouni C Copie-Bergman I Gaillard M Divine I Tabah-Fisch F Reyes C Haioun 2007 Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy Ann Oncol 18 1363 1368 1:STN:280:DC%2BD2svnt1eisw%3D%3D 10.1093/annonc/mdm133 17496309
27. N Di Renzo M Brugiatelli A Montanini ML Vigliotti G Cervetti AM Liberati S Luminari P Spedini G Giglio M Federico 2006 Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi Leuk lymphoma 47 473 479 10.1080/10428190500312295 16396771
28. F Morschhauser S Depil E Jourdan M Wetterwald R Bouabdallah G Marit P Solal-Celigny C Sebban B Coiffier N Chouaki F Bauters C Dumontet 2007 Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma Ann Oncol 18 370 375 1:STN:280: DC%2BD2s%2Fotlarsw%3D%3D 10.1093/annonc/mdl395 17074972